Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
In blow to Lula, Brazil Congress revives controversial environmental bill - 2Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- 3Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
- 4More people are addicted to marijuana, but fewer of them are seeking help, experts say
- 5Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
- Cyprus: War-related tourism concerns and climate change efforts
- The most effective method to Pick the Ideal Lab Precious stone Wedding band
- 'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
- What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- What's Your Number one Superhuman Film Made?
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- Help Your Business with Master Web based Promoting Arrangements
- Sports Shoes of 2024: Upgrade Execution and Solace
- The most effective method to Alter Your Kona SUV for Greatest Solace and Comfort
